Breaking News

DoD Awards Rigel $16.5M to Support Fostamatinib COVID Trials

Will evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Rigel Pharmaceuticals, Inc. has been awarded $16.5 million by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel’s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. The trial will evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters